RecruitingPhase 1NCT03311503
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Studying T-B+ severe combined immunodeficiency due to gamma chain deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- David Williams
- Principal Investigator
- Sung-Yun Pai, MDNational Institutes of Health (NIH)
- Intervention
- autologous CD34+ cell transduced with G2SCID vector(biological)
- Enrollment
- 12 enrolled
- Eligibility
- 0-5 years · MALE
- Timeline
- 2018 – 2028
Study locations (4)
- Mattel Children's Hospital - UCLA, Los Angeles, California, United States
- Emory University/Childrens Healthcare of Atlanta, Atlanta, Georgia, United States
- Boston Childrens Hospital, Boston, Massachusetts, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03311503 on ClinicalTrials.govOther trials for T-B+ severe combined immunodeficiency due to gamma chain deficiency
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03597594Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)St. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT03538899Autologous Gene Therapy for Artemis-Deficient SCIDUniversity of California, San Francisco
- RECRUITINGNCT00055172Genetic Basis of ImmunodeficiencyNational Heart, Lung, and Blood Institute (NHLBI)
See all trials for T-B+ severe combined immunodeficiency due to gamma chain deficiency →